LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

LLY

939

-0.18%↓

JNJ

185.88

-0.41%↓

UNH

326.5

-0.01%↓

NVS

126.44

+0.65%↑

ABT

124.05

-0.64%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

38.4 -1.87

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

37.72

Max

39.19

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	-2.7M -96M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+42.21% upside

Turustatistika
By TradingEconomics
Turukapital	-59M 3.2B
Eelmine avamishind	40.27
Eelmine sulgemishind	38.4

Uudiste sentiment

By Acuity

38%

62%

128 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. nov 2025, 23:51 UTC

Tulu

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5. nov 2025, 23:10 UTC

Tulu

DBS Third Quarter Net Dips 2.0%

5. nov 2025, 22:55 UTC

Tulu

Arm Holdings 2Q Profit Climbs on Record Demand

5. nov 2025, 22:23 UTC

Tulu

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5. nov 2025, 23:52 UTC

Tulu

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5. nov 2025, 23:49 UTC

Tulu

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5. nov 2025, 23:49 UTC

Tulu

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5. nov 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5. nov 2025, 23:42 UTC

Market Talk

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5. nov 2025, 23:12 UTC

Tulu

Nutrien 3Q Adj EPS 97c >NTR.T

5. nov 2025, 23:11 UTC

Tulu

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5. nov 2025, 23:10 UTC

Tulu

Nutrien 3Q Sales $6.01B >NTR.T

5. nov 2025, 23:10 UTC

Market Talk

Tulu

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5. nov 2025, 23:10 UTC

Tulu

Nutrien 3Q EPS 96c >NTR.T

5. nov 2025, 23:04 UTC

Tulu

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5. nov 2025, 23:03 UTC

Market Talk

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5. nov 2025, 22:55 UTC

Market Talk

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5. nov 2025, 22:55 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5. nov 2025, 22:51 UTC

Tulu

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5. nov 2025, 22:50 UTC

Tulu

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5. nov 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5. nov 2025, 22:43 UTC

Market Talk

Tulu

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5. nov 2025, 22:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. nov 2025, 22:36 UTC

Market Talk

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5. nov 2025, 22:20 UTC

Market Talk

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5. nov 2025, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5. nov 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5. nov 2025, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Responds to Delaware Chancery Court Ruling

5. nov 2025, 22:01 UTC

Tulu

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5. nov 2025, 22:01 UTC

Tulu

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

42.21% tõus

12 kuu keskmine prognoos

Keskmine 55.59 USD 42.21%

Kõrge 65 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

128 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.